http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 21 Aug 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26961790.html si-local-file:///var/storage/secattach/20260821/26961790.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26961790.html Fri, 21 Aug 2026 16:30:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26961790.html si-local-file:///var/storage/secattach/20260821/26961790.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26961790.html Fri, 21 Aug 2026 16:30:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Lipocine+Inc.++++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928158.html si-local-file:///var/storage/secattach/20260814/26928158.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Lipocine+Inc.++++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928158.html Fri, 14 Aug 2026 13:02:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Lipocine+Inc.++++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928158.html si-local-file:///var/storage/secattach/20260814/26928158.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Lipocine+Inc.++++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928158.html Fri, 14 Aug 2026 13:02:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891148.html si-local-file:///var/storage/secattach/20260807/26891148.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891148.html Fri, 07 Aug 2026 16:11:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891148.html si-local-file:///var/storage/secattach/20260807/26891148.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891148.html Fri, 07 Aug 2026 16:11:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891047.html si-local-file:///var/storage/secattach/20260807/26891047.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891047.html Fri, 07 Aug 2026 16:07:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891047.html si-local-file:///var/storage/secattach/20260807/26891047.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Grissinger+Michael/26891047.html Fri, 07 Aug 2026 16:07:00 -0400 LPCN O.13604276 http://www.streetinsider.com/Earnings/Lipocine+%28LPCN%29+Tops+Q2+EPS+by+12c/26867422.html <p>Lipocine (NASDAQ: LPCN) reported Q2 EPS of ($0.32), $0.12 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $190 million versus the consensus estimate of $162.5 thousand.</p><p>For earnings history and earnings-related data on Lipocine (LPCN) <a href="http://www.streetinsider.com/ec_earnings.php?q=LPCN">click here</a>.</p> http://www.streetinsider.com/Earnings/Lipocine+%28LPCN%29+Tops+Q2+EPS+by+12c/26867422.html Tue, 04 Aug 2026 16:48:07 -0400 LPCN http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/Press+Releases/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:LPCN" idsrc="xmltag.org" >Lipocine Inc.</span> (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended <chron>June 30, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS801167/lipocine-logo.jpg?id=OA2822492" title="" alt="" /> http://www.streetinsider.com/PRNewswire/Lipocine+Announces+Financial+Results+for+the+Second+Quarter+Ended+June+30%2C+2026/26861960.html Tue, 04 Aug 2026 08:00:00 -0400 A.42836255 LPCN O.13604276 O.29746659 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+04/26860844.html si-local-file:///var/storage/secattach/20260804/26860844.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+04/26860844.html Tue, 04 Aug 2026 06:09:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+04/26860844.html si-local-file:///var/storage/secattach/20260804/26860844.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+04/26860844.html Tue, 04 Aug 2026 06:09:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Lipocine+Inc.+++++++++++++For%3A+Jun+30/26860806.html si-local-file:///var/storage/secattach/20260804/26860806.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Lipocine+Inc.+++++++++++++For%3A+Jun+30/26860806.html Tue, 04 Aug 2026 06:05:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Lipocine+Inc.+++++++++++++For%3A+Jun+30/26860806.html si-local-file:///var/storage/secattach/20260804/26860806.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Lipocine+Inc.+++++++++++++For%3A+Jun+30/26860806.html Tue, 04 Aug 2026 06:05:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26855240.html si-local-file:///var/storage/secattach/20260803/26855240.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26855240.html Mon, 03 Aug 2026 09:35:00 -0400 LPCN O.13604276 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26855240.html si-local-file:///var/storage/secattach/20260803/26855240.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lipocine+Inc.+++++++++++++For%3A+Aug+03/26855240.html Mon, 03 Aug 2026 09:35:00 -0400 LPCN O.13604276 http://www.streetinsider.com/Board+Changes/Lipocine+names+former+Johnson+%26+Johnson+executive+to+its+board/26854180.html <p>Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Michael J. Grissinger to its board of directors, effective Aug. 3, 2026, according to a company press release.</p> <p>Grissinger spent more than two decades at Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. Before Johnson & Johnson, he spent 12 years at Ciba-Geigy in finance, marketing, and business development.</p> <p>He currently serves on the boards of Aprea Therapeutics (NASDAQ: APRE) and Adicet Bio (NASDAQ: ACET), and advises several privately held biotech companies. Grissinger http://www.streetinsider.com/Board+Changes/Lipocine+names+former+Johnson+%26+Johnson+executive+to+its+board/26854180.html Mon, 03 Aug 2026 08:00:56 -0400 A.00437200 A.03263046 A.50210956 ACET APRE LPCN O.01490590 O.02094321 O.13604276 O.37270417 O.42040581 O.48111428 http://www.streetinsider.com/Board+Changes/Lipocine+names+former+Johnson+%26+Johnson+executive+to+its+board/26854180.html <p>Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Michael J. Grissinger to its board of directors, effective Aug. 3, 2026, according to a company press release.</p> <p>Grissinger spent more than two decades at Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. Before Johnson & Johnson, he spent 12 years at Ciba-Geigy in finance, marketing, and business development.</p> <p>He currently serves on the boards of Aprea Therapeutics (NASDAQ: APRE) and Adicet Bio (NASDAQ: ACET), and advises several privately held biotech companies. Grissinger http://www.streetinsider.com/Board+Changes/Lipocine+names+former+Johnson+%26+Johnson+executive+to+its+board/26854180.html Mon, 03 Aug 2026 08:00:56 -0400 A.00437200 A.03263046 A.50210956 ACET APRE LPCN O.01490590 O.02094321 O.13604276 O.37270417 O.42040581 O.48111428